BioNTech SE annual gross margin
2017
2018
2019
2020
2021
2022
2023
2024
2025
BioNTech SE Gross Margin Growth & History (BNTX)
BioNTech SE's gross margin was 77.64% for fiscal 2025.
View full BioNTech SE company overviewBioNTech SE annual gross margin history
| Fiscal year | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 77.64% | −2.69 pp |
| 2024 | 2024-12-31 | 80.32% | −3.97 pp |
| 2023 | 2023-12-31 | 84.29% | +1.60 pp |
| 2022 | 2022-12-31 | 82.70% | −1.96 pp |
| 2021 | 2021-12-31 | 84.66% | −3.05 pp |
| 2020 | 2020-12-31 | 87.70% | +3.70 pp |
| 2019 | 2019-12-31 | 84.00% | −5.27 pp |
| 2018 | 2018-12-31 | 89.27% | +4.40 pp |
| 2017 | 2017-12-31 | 84.87% | — |
BioNTech SE gross margin trends
Over the last five fiscal years, BioNTech SE's gross margin decreased from 87.70% to 77.64%, a change of −10.07 percentage points.
About the metric
What gross margin means
Gross margin measures the percentage of revenue remaining after the direct costs of producing goods or services. It helps show how efficiently a company turns sales into gross profit before operating expenses.
Calculation and source
How gross margin is calculated
TickerStat calculates gross margin as SEC-reported gross profit divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review BioNTech SE source filings ↗Community posts
BioNTech reports longer survival in exploratory lung-cancer trial stage
BioNTech ($BNTX) and OncoC4 reported updated results for gotistobart in previously treated advanced squamous non-small cell lung cancer. Median overall survival reached 18.5 months versus 10 months with docetaxel in the non-pivotal first st ...
